Chris Ogden | executive |
Sean McCarthy | executive |
Etzer Darout | analyst |
Malcolm Kuno | analyst |
Good evening, everyone. Thank you for standing by, and welcome to the CytomX Therapeutics Second Quarter 2024 Financial Results Call. Please be advised that today's call is being recorded. I will now hand the call over to your host for today, Chris Ogden, CytomX's Chief Financial Officer. Please go ahead.